Mendus AB Valuation
| IMMU Stock | SEK 8.15 0.03 0.37% |
At this time, the firm appears to be overvalued. Mendus AB secures a last-minute Real Value of kr7.25 per share. The latest price of the firm is kr8.15. Our model forecasts the value of Mendus AB from analyzing the firm fundamentals such as Shares Outstanding of 199.4 M, operating margin of (69.15) %, and Return On Equity of -0.21 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Mendus AB's price fluctuation is slightly risky at this time. Calculation of the real value of Mendus AB is based on 3 months time horizon. Increasing Mendus AB's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Mendus AB's intrinsic value may or may not be the same as its current market price of 8.15, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.15 | Real 7.25 | Hype 8.15 | Naive 7.21 |
The intrinsic value of Mendus AB's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mendus AB's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mendus AB helps investors to forecast how Mendus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mendus AB more accurately as focusing exclusively on Mendus AB's fundamentals will not take into account other important factors: Mendus AB Total Value Analysis
Mendus AB is currently anticipated to have takeover price of 607.17 M with market capitalization of 427.98 M, debt of 0, and cash on hands of 155.31 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Mendus AB fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
607.17 M | 427.98 M | 0 | 155.31 M |
Mendus AB Asset Utilization
One of the ways to look at asset utilization of Mendus is to check how much profit was generated for every dollar of assets it reports. Mendus AB secures a negative usage of assets of -0.11 %, losing kr0.001114 for each kronor of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each kronor of assets it secures. Strictly speaking, asset utilization of Mendus AB shows how discouraging it operates for each kronor spent on its assets.Mendus AB Ownership Allocation
Mendus AB maintains a total of 199.4 Million outstanding shares. Mendus AB holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Mendus AB Profitability Analysis
Net Loss for the year was (130.1 M) with profit before overhead, payroll, taxes, and interest of 6 K.About Mendus AB Valuation
The stock valuation mechanism determines Mendus AB's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Mendus AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mendus AB. We calculate exposure to Mendus AB's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mendus AB's related companies.Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct Mendus AB's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Mendus AB's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Mendus AB's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Mendus AB's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Mendus AB's revenue streams: Identify Mendus AB's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Mendus AB's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Mendus AB's growth potential: Evaluate Mendus AB's management, business model, and growth potential.
- Determine Mendus AB's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Mendus AB's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.